Veronique Lecault - Jan 1, 2025 Form 4 Insider Report for AbCellera Biologics Inc. (ABCL)

Role
Chief Operating Officer, Director
Signature
Tryn Stimart, attorney-in-fact
Stock symbol
ABCL
Transactions as of
Jan 1, 2025
Transactions value $
$0
Form type
4
Date filed
1/3/2025, 03:40 PM
Previous filing
Jun 24, 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABCL Share option (right to buy) Award $0 +832K +21.73% $0.00 4.66M Jan 1, 2025 Common Shares 832K $2.93 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to such option vest and become exercisable monthly in substantially equal installments over a four-year period, with the first tranche vested on January 1, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date.